IS6957A - Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim - Google Patents

Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim

Info

Publication number
IS6957A
IS6957A IS6957A IS6957A IS6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A
Authority
IS
Iceland
Prior art keywords
triacetetracyclo
tatrate
pentaene
hexadecene
salts
Prior art date
Application number
IS6957A
Other languages
English (en)
Other versions
IS2217B (is
Inventor
Everett Bogle David
Robert Rose Peter
Robert Williams Glenn
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6957A publication Critical patent/IS6957A/is
Publication of IS2217B publication Critical patent/IS2217B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
IS6957A 2001-05-14 2003-09-15 Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni. IS2217B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086101P 2001-05-14 2001-05-14
PCT/IB2002/001437 WO2002092089A1 (en) 2001-05-14 2002-04-26 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
IS6957A true IS6957A (is) 2003-09-15
IS2217B IS2217B (is) 2007-03-15

Family

ID=23117845

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6957A IS2217B (is) 2001-05-14 2003-09-15 Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni.

Country Status (47)

Country Link
US (2) US6890927B2 (is)
EP (1) EP1392307B1 (is)
JP (1) JP3779682B2 (is)
KR (1) KR100551184B1 (is)
CN (1) CN100370987C (is)
AP (1) AP1473A (is)
AR (1) AR033635A1 (is)
AT (1) ATE302607T1 (is)
AU (1) AU2002253482B2 (is)
BG (1) BG66408B1 (is)
BR (1) BR0209605A (is)
CA (1) CA2447405C (is)
CR (1) CR7080A (is)
CZ (1) CZ304763B6 (is)
DE (1) DE60205742T2 (is)
DK (1) DK1392307T3 (is)
DO (1) DOP2002000392A (is)
EA (1) EA005528B1 (is)
EC (2) ECSP034849A (is)
EE (1) EE05441B1 (is)
EG (1) EG24228A (is)
ES (1) ES2246396T3 (is)
GE (1) GEP20053712B (is)
GT (1) GT200200084A (is)
HR (1) HRP20030910B1 (is)
HU (1) HU229867B1 (is)
IL (2) IL157933A0 (is)
IS (1) IS2217B (is)
MA (1) MA27020A1 (is)
ME (1) ME00466B (is)
MX (1) MXPA03010364A (is)
MY (1) MY127807A (is)
NO (1) NO326148B1 (is)
NZ (1) NZ528210A (is)
OA (1) OA12599A (is)
PA (1) PA8545101A1 (is)
PE (1) PE20021065A1 (is)
PL (1) PL214876B1 (is)
PT (1) PT1392307E (is)
RS (1) RS50814B (is)
SI (1) SI1392307T1 (is)
SK (1) SK287170B6 (is)
TN (1) TNSN03113A1 (is)
TW (1) TWI262078B (is)
UA (1) UA73422C2 (is)
WO (1) WO2002092089A1 (is)
ZA (1) ZA200307235B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
RU2272629C2 (ru) 2001-11-30 2006-03-27 Пфайзер Продактс Инк. Фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0(2,11).0(4,9)]гексадека-2( 11),3,5,7,9-пентаена
BRPI0410219A (pt) * 2003-05-20 2006-05-09 Pfizer Prod Inc composições farmacêuticas de vareniclina
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1763521A1 (en) * 2004-06-30 2007-03-21 Eli Lilly and Company 1- (indole-6-carbonyl-d-phenylglycinyl)-4- (l-methylpiperidin-4- yl) piperazine d-tartrate
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
MX2007004495A (es) * 2004-10-15 2007-05-10 Pfizer Prod Inc Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
ATE411994T1 (de) * 2005-02-24 2008-11-15 Pfizer Prod Inc Herstellung eines substituierten chinoxalins von hoher reinheit
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009508880A (ja) * 2006-02-21 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アルモダフィニルの新規な結晶形とその調製方法
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
WO2009109651A1 (en) * 2008-03-06 2009-09-11 Medichem, S.A. SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
EP2262780A4 (en) * 2008-03-06 2012-01-25 Reddys Lab Ltd Dr TARTRATE OF VARENICLINE AMORPHOUS
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2440187A2 (en) 2009-06-10 2012-04-18 Actavis Group PTC ehf. Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US9090623B2 (en) 2012-04-13 2015-07-28 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Compound JK12A and preparation thereof
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
WO2021259396A2 (zh) 2021-08-20 2021-12-30 威智医药有限公司 一种亚硝胺杂质、能够减少亚硝胺杂质生成的伐尼克兰药物组合物及其制备与应用
KR20230068877A (ko) 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) * 2021-11-22 2023-05-09 浙江车头制药股份有限公司 一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
AU2023295214A1 (en) 2022-06-14 2025-03-06 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
EP4611896A1 (en) 2022-11-04 2025-09-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko) 2023-01-18 2024-07-25 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
TWI236930B (en) * 2000-05-26 2005-08-01 Pfizer Prod Inc Reactive crystallization method to improve particle size

Also Published As

Publication number Publication date
CN100370987C (zh) 2008-02-27
TWI262078B (en) 2006-09-21
EP1392307A1 (en) 2004-03-03
CZ304763B6 (cs) 2014-10-01
BR0209605A (pt) 2004-03-23
KR20040010638A (ko) 2004-01-31
US6890927B2 (en) 2005-05-10
PT1392307E (pt) 2005-11-30
CZ20032916A3 (cs) 2004-09-15
SK287170B6 (sk) 2010-02-08
US7265119B2 (en) 2007-09-04
PA8545101A1 (es) 2003-09-05
AP1473A (en) 2005-09-30
US20050148591A1 (en) 2005-07-07
IS2217B (is) 2007-03-15
NZ528210A (en) 2005-04-29
ES2246396T3 (es) 2006-02-16
AR033635A1 (es) 2003-12-26
NO326148B1 (no) 2008-10-06
NO20035036D0 (no) 2003-11-13
MA27020A1 (fr) 2004-12-20
CN1509174A (zh) 2004-06-30
EE05441B1 (et) 2011-08-15
EE200300556A (et) 2004-04-15
GEP20053712B (en) 2005-12-26
ECSP034850A (es) 2003-12-24
HK1062645A1 (en) 2004-11-19
DOP2002000392A (es) 2002-11-15
BG108343A (bg) 2004-12-30
CR7080A (es) 2006-08-09
EG24228A (en) 2008-11-10
OA12599A (en) 2006-06-08
HRP20030910B1 (hr) 2011-11-30
PL366551A1 (en) 2005-02-07
JP2004533446A (ja) 2004-11-04
CA2447405A1 (en) 2002-11-21
HRP20030910A2 (en) 2004-02-29
ECSP034849A (es) 2003-12-24
ME00466B (me) 2011-10-10
WO2002092089A1 (en) 2002-11-21
TNSN03113A1 (fr) 2005-12-23
GT200200084A (es) 2003-09-12
NO20035036L (no) 2003-11-13
EA005528B1 (ru) 2005-04-28
AP2002002523A0 (en) 2002-06-30
DE60205742T2 (de) 2006-05-11
PE20021065A1 (es) 2002-11-21
RS50814B (sr) 2010-08-31
EA200301121A1 (ru) 2004-02-26
US20030166701A1 (en) 2003-09-04
IL157933A0 (en) 2004-03-28
HU229867B1 (en) 2014-10-28
DK1392307T3 (da) 2005-11-07
EP1392307B1 (en) 2005-08-24
HUP0304088A2 (hu) 2004-04-28
CA2447405C (en) 2006-10-17
MY127807A (en) 2006-12-29
HUP0304088A3 (en) 2011-11-28
PL214876B1 (pl) 2013-09-30
ATE302607T1 (de) 2005-09-15
UA73422C2 (en) 2005-07-15
ZA200307235B (en) 2004-09-16
MXPA03010364A (es) 2004-03-16
SI1392307T1 (sl) 2005-12-31
AU2002253482B2 (en) 2007-09-06
KR100551184B1 (ko) 2006-02-13
JP3779682B2 (ja) 2006-05-31
BG66408B1 (bg) 2014-01-31
DE60205742D1 (de) 2005-09-29
IL157933A (en) 2013-07-31
SK13362003A3 (en) 2004-11-03
YU86703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
FI20011478L (fi) Farmaseuttinen koostumus
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
ITTO20000779A0 (it) Composizioni farmaceutiche.
NO20033556L (no) Farmasöytiske formuleringer
DE60203581D1 (de) Alfa-beta Titanlegierung
NO20040125L (no) Enterale formuleringer
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
DE60234409D1 (de) Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EE200300416A (et) Ravimvorm
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
EE200300589A (et) Ravimkoostised
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
FI20022128L (fi) Farmaseuttinen koostumus
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DK1235809T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler